Nephrology Times
Nephrology Times
Advertisement
Charlotte RobinsonIgA Nephropathy | February 14, 2025
Researchers reported the progression of kidney function throughout the course of IgA nephropathy.
Read More
Charlotte RobinsonIgA Nephropathy | February 13, 2025
Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks?
Charlotte RobinsonKidney Transplantation | February 13, 2025
The KidneyVault Portable Renal Perfusion System has been used in human kidney transplants for the first time.
Jessica Strawn, MA, RD, LDNephrology Times | February 12, 2025
Jessica Strawn explains why being aware of patients' past trauma should be of concern to kidney care providers.
Charlotte RobinsonHyperkalemia | February 12, 2025
A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia.
Charlotte RobinsonChronic Kidney Disease | February 12, 2025
Eli Lilly ended a phase II trial of volenrelaxin in chronic kidney disease "due to a lack of foreseeable clinical benefit."
Charlotte RobinsonNephrology Times | February 11, 2025
Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis.
Victoria SochaChronic Kidney Disease | February 11, 2025
Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is unclear.
Charlotte RobinsonGout | February 11, 2025
A review and meta-analysis assessed the influence of SGLT2i therapy on clinically relevant hyperuricemic events.
Charlotte RobinsonChronic Kidney Disease | February 10, 2025
Using NURTuRE-CKD data, researchers studied kidney outcomes and heterogeneity of risk by primary renal diagnosis.
Charlotte RobinsonKidney Transplantation | February 7, 2025
The NKF will invest in the NoMo Kidney Pump, a continuous perfusion system to modernize kidney preservation and storage.
Charlotte RobinsonNephrology Times | February 7, 2025
The FDA has granted ODD and RPDD designations to ABO-101 to treat primary hyperoxaluria type 1 (PH1).
Charlotte RobinsonChronic Kidney Disease | February 7, 2025
Monlunabant failed in a study of its use in DKD, but Novo Nordisk had positive news about other kidney treatments in 2024.
Charlotte RobinsonWCN 2025 | February 10, 2025
Can SZC help with RAASi maximization without resultant hyperkalemia in patients with HFrEF and CKD?
Charlotte RobinsonWCN 2025 | February 10, 2025
Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.
Charlotte RobinsonWCN 2025 | February 6, 2025
Current eligibility criteria for simultaneous heart and kidney transplantation may be subject to eGFRcr errors.
Charlotte RobinsonWCN 2025 | February 6, 2025
How accurately and efficiently does artificial intelligence perform clinical prescreening compared with nephrologists?
Charlotte RobinsonWCN 2025 | February 6, 2025
The WRAPSODY stent may help restore circuit patency when stenosis or occlusion occurs within the AVG or AVF for hemodialysis.
Channel Your EnthusiasmNephrology Times | February 6, 2025
Listen to part 2 of the discussion of Chapter 16 of Dr. Burton Rose's book, focused on edematous states.
Charlotte RobinsonWCN 2025 | February 6, 2025
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
Advertisement
Advertisement
Advertisement
Latest News

February 14, 2025